Patents by Inventor Samuel E. Perkins
Samuel E. Perkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7855272Abstract: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: GrantFiled: August 24, 2009Date of Patent: December 21, 2010Assignees: Bioresearch Ireland, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Patent number: 7834151Abstract: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: GrantFiled: August 24, 2009Date of Patent: November 16, 2010Assignee: The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Patent number: 7816494Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: GrantFiled: August 24, 2009Date of Patent: October 19, 2010Assignee: The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Publication number: 20100113349Abstract: An isolated extracellular matrix-binding protein, designated as SdrE and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: ApplicationFiled: August 24, 2009Publication date: May 6, 2010Inventors: Joseph M. PATTI, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
-
Publication number: 20100081616Abstract: An isolated extracellular matrix-binding protein, designated as SdrD and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: ApplicationFiled: August 24, 2009Publication date: April 1, 2010Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
-
Publication number: 20100008943Abstract: An isolated extracellular matrix-binding protein, designated as SdrC and its corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: ApplicationFiled: August 24, 2009Publication date: January 14, 2010Inventors: Joseph M. Patti, Timothy J. Foster, Elizabet Joseffson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Patent number: 7381793Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.Type: GrantFiled: December 24, 2003Date of Patent: June 3, 2008Assignees: Inhibitex, Inc., BioResearch Ireland, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins
-
Publication number: 20040254354Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials.Type: ApplicationFiled: December 24, 2003Publication date: December 16, 2004Inventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A.O. Hook, Samuel E. Perkins
-
Patent number: 6680195Abstract: Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of S. aureus infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of S. aureus to wounds or biomaterials. ClfB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen.Type: GrantFiled: November 25, 1998Date of Patent: January 20, 2004Assignees: Inhibitex, Inc., Bioresearch Ireland, The Texas A&M University SystemInventors: Joseph M. Patti, Timothy J. Foster, Elisabet Josefsson, Deidre Ni Eidhin, Magnus A. O. Hook, Samuel E. Perkins